Registration is open to the general population; to participate, you must be between 18 and 85 years old, have not tested positive for covid-19 and not be pregnant
Pfizer still has 360 vacancies for vaccine volunteers in SP
29/09/2020 – 15h08 (Updated 29/09/2020 – 15h10)
Cepic (São Paulo Center for Clinical Investigation), in São Paulo, responsible for testing the vaccine against covid-19 produced by Pfizer, said on Tuesday (29) that it is still accepting volunteers for the study, which is in the third and last stage. There are 360 vacancies.
Unlike the Oxford and Coronavac vaccine tests carried out in the country, restricted to health professionals, those of the Pfizer vaccine are open to the population. The main criterion is to be exposed to the virus in some way, for example, using public transport, according to Cepic.
Read also: Know the pros and cons of vaccines against covid-19 tested in Brazil
In total, there will be 1,350 volunteers at Cepic, of which 700 have already received the second dose of the vaccine, according to the research center. Registration for volunteers can be made through the Cepic website. It is necessary to be between 18 and 85 years old, not to have tested positive for covid-19 and not to be pregnant or to be breastfeeding.
By participating, the volunteer will be able to receive the experimental vaccine or placebo and will be accompanied for two years. It is not possible to know which substance the participant received and he will not be able to get another vaccine against covid-19 during this period. This protocol even scared off volunteers.
Pfizer has been testing in Brazil since August 5 at Cepic and the philanthropic institution Obras Social Irmã Dulce (OSID), in Salvador.
The Pfizer vaccine, developed in partnership with the German company BioNTech, is considered innovative. It is based on genetic material, known as messenger RNA. It carries information for cells to produce protein. In the case of the new coronavirus, it would provide instructions on how to produce the spike protein, present in the Sars-CoV-2 virus, inducing the body’s immune response to covid-19. The company is negotiating the feasibility of producing the vaccine in the country, according to Pfizer.
*Trainee R7 under the supervision of Deborah Giannini